- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03664141
Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study) (ICON-HP)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting
The study will be performed in two parts: 1) The pharmacokinetic (PK) part and 2) The appetite and nutritional evaluation part.
The PK part of study will be conducted in open label manner on 10 end stage kidney disease (ESKD) patients receiving maintenance hemodialysis (MHD) treatment. For the PK part, a starting dose of cannabis oil -1 drop of 3% cannabis oil once a day [each drop contain 1.2 mg CBD (cannabidiol) and 1.2 mg of ∆9-THC (∆9-tetrahydrocannabinol)], was judged to be safe for a first-in-MHD patient's administration. Escalation to the next higher dose and any dose adjustments of the next dose levels will be based on safety and tolerability results of the previously administered dose and available PK data of previous dose groups. Once the first dosage proved to be safe, there will be a 2 fold increase from the first dose level (2 drops once a day) to the second dose level. The dose levels will be increased by 2-fold from the previous dose level, until basal hunger and prospective consumption ratings assessed by the visual analogue scale (VAS) will increase at least by 10 mm between screening and the study visits (change-from-baseline) . PK parameters will be evaluated after first dosage administration and after dosage increased.
The appetite and nutritional evaluation part of study will be conducted as a 3-month, double-blind, parallel-group, placebo-controlled, single center study. The study population will include 30 ESKD patients receiving MHD treatment with different degrees of protein-energy wasting (PEW) defined as malnutrition-inflammation score (MIS) above 6. A total of 30 subjects will be randomized to treatment with either cannabis oil or matching placebo.
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Zrifin, Israel, 70300
- Asaf ha Rofeh, MC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age > 18 years, on MHD hemodialysis treatment at least 3 months
- Stable and adequate hemodialysis treatment three months prior to participation in study as defined by Kt/V > 1.2 and/or hemodialysis performed 4 hours 3 times weekly
- Patients with Malnutrition-Inflammation Score (MIS) ≥ 6
- Informed consent obtained before any trial-related activities
Exclusion Criteria:
- Previous or current use in cannabis or marijuana
- Critical illness as defined by the need of respiratory or circulatory support
- Known or suspected allergy to trial products
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using contraceptive methods
- Patients with active malignant disease or liver cirrhosis
- Actively symptomatic gastrointestinal bleeding and inflammatory bowel disease
- Patients on chronic treatment with steroids on doses > 10 mg/day Prednisone (or equivalent)
- Patients treated with immunosuppressive agents
- Patients receiving any of the following medications: Astemizole, Cisapride, Pimozide or Terfenadine
Patients suffering from:
- Acute vasculitis
- Severe systemic infections
- Severe Heart failure (NYHA class IV)
- Severe hepatic disease, defined as ALT or AST levels >3 times upper normal range
- Mental incapacity, unwillingness or language barrier
- Any condition judged by the investigator to interfere with trial participation or evaluation of results or to be potentially hazardous to the patient
- A significant history of alcohol, drug or solvent abuse
- History of schizophrenia, affective disorder, history of psychiatric hospitalization and diagnosed anxiety disorder
- The receipt of any investigational drug within 1 month prior to initiating of this study
- Scheduled renal transplantation (fixed date).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
1 drop of regular oil for food labeled as 3% cannabis oil once a day during 3 months
|
Treatment with cannabis oil
Treatment with placebo (Regular Oil)
|
Experimental: Cannabis oil group
1 drop of 3% cannabis oil once a day during 3 months
|
Treatment with cannabis oil
Treatment with placebo (Regular Oil)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall incidence and prevalence of adverse events
Time Frame: For 5 months from the day of randomization
|
Overall incidence and prevalence of adverse events
|
For 5 months from the day of randomization
|
Change in appetite assessed by the Visual Analogue Scale (VAS).
Time Frame: For 5 months from the day of randomization
|
VAS, 100 mm in length with words anchored at each end, expressing the most positive (=100) and the most negative rating (=0), will be used to assess specific domains of appetite separately: hunger, satiety, fullness, prospective food consumption.
Each domain will be measured by the 0-100mm scale as mentioned above.
|
For 5 months from the day of randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in nutritional status assessed by the Malnutrition-Inflammation Score (MIS).
Time Frame: For 5 months from the day of randomization
|
MIS consists of four sections (nutritional history, physical examination, body mass index [BMI], and laboratory values) and 10 components.
Each MIS component has four levels of severity from 0 (normal) to 3 (very severe).
The sum of all 10 components results in an overall score ranging from 0 (normal) to 30 (severely malnourished).
|
For 5 months from the day of randomization
|
Change in Health Related Quality of Life assessed by short form 36 (SF-36) quality of life (QoL) scoring system
Time Frame: For 5 months from the day of randomization
|
SF-36 consists of 36 questions, 35 of which are compressed into eight multi-item scales: (1) physical functioning; (2) role-physical (3) bodily pain ; (4) general health; (5) vitality ; (6) social functioning (7) role-emotional and (8) mental health. In the SF36 scoring system, the scales are assessed quantitatively, each on the basis of answers to two to ten multiple choice questions, and a score between 0 and 100 is then calculated on the basis of well-defined guidelines, with a higher score indicating a better state of health. |
For 5 months from the day of randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Assaf Harofeh MC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis
-
National Taiwan University HospitalCompletedHemodialysis Complication | Hemodialysis-Induced SymptomTaiwan
-
Ain Shams UniversityCompleted
-
Imperial College Healthcare NHS TrustCompletedHemodialysisUnited Kingdom
-
Lawson Health Research InstituteUnknown
-
Tufts Medical CenterWithdrawn
-
Federico II UniversityUnknown
-
Hospital Clinic of BarcelonaSocietat Catalana de NefrologiaCompleted
-
Brigham and Women's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Angion Biomedica CorpNucleus Network LtdNot yet recruitingHemodialysisUnited States
Clinical Trials on Cannabis oil
-
Wolfson Medical CenterUnknownDystonia | SpasticityIsrael
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Rambam Health Care CampusCompleted1- Cancer Patients During Chemotherapy Treatment | 2- Use of Cannabis Comparing to Control Without Cannabis UseIsrael
-
TO PharmaceuticalsWithdrawn
-
M. H MediCane Ltd.RecruitingDementia | Alzheimer Disease | Agitation,Psychomotor | Disruptive BehaviorIsrael
-
Germans Trias i Pujol HospitalIstituto Superiore di Sanità; Fundació Institut Germans Trias i PujolCompletedHealthy Subjects | Cannabis UseSpain
-
Fondation pour l'accueil et l'hébérement des personnes...University Hospital, GenevaRecruitingDementia With Behavioral DisturbanceSwitzerland
-
Aurora Cannabis IncHamilton Health Sciences Corporation; Ontario Clinical Oncology Group (OCOG)Unknown
-
New Age Ventures LLCKGK Science Inc.CompletedHealthy | CannabisCanada
-
Assaf-Harofeh Medical CenterSeach Sarid Ltd; Canndoc LtdActive, not recruitingAutism Spectrum DisorderIsrael